Polysaccharide-based nucleic acid nanoformulations

Advanced Drug Delivery Reviews

Volumn 65, Issue 9, 2013, Pages 1123-1147

  Raemdonck, Koen ^a   Martens, Thomas F ^a   Braeckmans, Kevin ^a   Demeester, Jo ^a   De Smedt, Stefaan C ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Chitosan; Cyclodextrin; Dextran; Gene therapy; Hyaluronic acid; Nanomedicine; Plasmid DNA; SiRNA

Indexed keywords

BIOCOMPATIBILITY; BIOPOLYMERS; CHITOSAN; CONTROLLED DRUG DELIVERY; CYCLODEXTRINS; DEXTRAN; GENE THERAPY; HYALURONIC ACID; MEDICAL NANOTECHNOLOGY; NUCLEIC ACIDS; POLYSACCHARIDES; TARGETED DRUG DELIVERY;

DRUG LOADED NANOPARTICLE; INTRACELLULAR DELIVERY; NATURAL POLYSACCHARIDE; NUCLEIC ACID DELIVERIES; PHARMACEUTICAL APPLICATIONS; PLASMID DNA; SIRNA; THERAPEUTIC APPLICATION;

BIOMOLECULES;

ABC TRANSPORTER; ALGINIC ACID; AMPHOPHILE; ANTISENSE OLIGONUCLEOTIDE; ARABINOGALACTAN; BETA GLUCAN; CHITOSAN; CYCLODEXTRIN; DEXTRAN; DEXTRAN SULFATE; DIETHYLAMINOETHYLDEXTRAN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; HEPATITIS B ANTIGEN; HYALURONIC ACID; NANOCARRIER; NANOPARTICLE; NUCLEIC ACID; PECTIN; PHOTOSENSITIZING AGENT; PLASMID DNA; PLATELET DERIVED GROWTH FACTOR; POLYELECTROLYTE; POLYGLACTIN; POLYSACCHARIDE; PULLULAN; QUANTUM DOT; SALBUTAMOL; SMALL INTERFERING RNA; UNINDEXED DRUG;

ARTICLE; BIOCOMPATIBILITY; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CELLULAR IMMUNITY; CHEMICAL STRUCTURE; COMPLEX FORMATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; DRUG TRANSPORT; GENE DELIVERY SYSTEM; GENE SILENCING; GENE TRANSFER; HUMORAL IMMUNITY; IMMUNOREGULATION; INTRACELLULAR TRANSPORT; LIPOSOMAL GENE DELIVERY SYSTEM; MATERIAL COATING; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; NANOENCAPSULATION; NANOFORMULATION; NANOMEDICINE; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PHOTOCHEMICAL INTERNALIZATION; POLYMERIZATION; PRIORITY JOURNAL; THYROID CARCINOMA;

CHITOSAN; CYCLODEXTRIN; DEXTRAN; GENE THERAPY; HYALURONIC ACID; NANOMEDICINE; PLASMID DNA; SIRNA;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HUMANS; NANOPARTICLES; NUCLEIC ACIDS; POLYSACCHARIDES;

EID: 84884279731     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.05.002     Document Type: Review

References (265)

1. Davidson B.L., Mccray P.B. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 2011, 12:329-340.
2. Remaut K., Sanders N.N., De Geest B.G., Braeckmans K., Demeester J., De Smedt S.C. Nucleic acid delivery: where material sciences and bio-sciences meet. Mater. Sci. Eng. R. 2007, 58:117-161.
3. Ginn S.L., Alexander I.E., Edelstein M.L., Abedi M.R., Wixon J. Gene therapy clinical trials worldwide to 2012 an update. J. Gene Med. 2013, 15:65-77.
4. Patil S.D., Rhodes D.G., Burgess D.J. DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J. 2005, 7:E61-E77.
5. Villemejane J., Mir L.M. Physical methods of nucleic acid transfer: general concepts and applications. Br. J. Pharmacol. 2009, 157:207-219.
6. Raemdonck K., Vandenbroucke R.E., Demeester J., Sanders N.N., De Smedt S.C. Maintaining the silence: reflections on long-term RNAi. Drug Discov. Today 2008, 13:917-931.
7. Green J.J., Langer R., Anderson D.G. A combinatorial polymer library approach yields insight into nonviral gene delivery. Acc. Chem. Res. 2008, 41:749-759.
8. Nel A.E., Madler L., Velegol D., Xia T., Hoek E.M.V., Somasundaran P., Klaessig F., Castranova V., Thompson M. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 2009, 8:543-557.
9. Yoo J.W., Chambers E., Mitragotri S. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr. Pharm. Des. 2010, 16:2298-2307.
10. Peer D., Karp J.M., Hong S., FaroKHzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
11. Vercauteren D., Rejman J., Martens T.F., Demeester J., De Smedt S.C., Braeckmans K. On the cellular processing of non-viral nanomedicines for nucleic acid delivery: mechanisms and methods. J. Control. Release 2012, 161:566-581.
12. Symens N., Soenen S.J., Rejman J., Braeckmans K., De Smedt S.C., Remaut K. Intracellular partitioning of cell organelles and extraneous nanoparticles during mitosis. Adv. Drug Deliv. Rev. 2012, 64:78-94.
13. Liu Z., Jiao Y., Wang Y., Zhou C., Zhang Z. Polysaccharides-based nanoparticles as drug delivery systems. Adv. Drug Deliv. Rev. 2008, 60:1650-1662.
14. Mizrahy S., Peer D. Polysaccharides as building blocks for nanotherapeutics. Chem. Soc. Rev. 2012, 41:2623-2640.
15. Chauvierre C., Manchanda R., Labarre D., Vauthier C., Marden M.C., Leclerc L. Artificial oxygen carrier based on polysaccharides-poly(alkylcyanoacrylates) nanoparticle templates. Biomaterials 2010, 31:6069-6074.
16. Lemarchand C., Gref R., Couvreur P. Polysaccharide-decorated nanoparticles. Eur. J. Pharm. Biopharm. 2004, 58:327-341.
17. Zhang H.L., Ma Y., Sun X.L. Recent developments in carbohydrate-decorated targeted drug/gene delivery. Med. Res. Rev. 2010, 30:270-289.
18. Lesley J., Hascall V.C., Tammi M., Hyman R. Hyaluronan binding by cell surface CD44. J. Biol. Chem. 2000, 275:26967-26975.
19. Van T., Hennink W.E. Biodegradable dextran hydrogels for protein delivery applications. Expert Rev. Med. Devices 2007, 4:147-164.
20. Varshosaz J. Dextran conjugates in drug delivery. Expert Opin. Drug Deliv. 2012, 9:509-523.
21. Mehvar R. Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J. Control. Release 2000, 69:1-25.
22. Heinze T., Liebert T., Heublein B., Hornig S. Functional polymers based on dextran. Polysaccharides II 2006, 205:199-291.
23. Raemdonck K., Van Thienen T.G., Vandenbroucke R.E., Sanders N.N., Demeester J., De Smedt S.C. Dextran microgels for time-controlled delivery of siRNA. Adv. Funct. Mater. 2008, 18:993-1001.
24. Raemdonck K., Demeester J., De Smedt S. Advanced nanogel engineering for drug delivery. Soft Matter 2009, 5:707-715.
25. Raemdonck K., Naeye B., Buyens K., Vandenbroucke R.E., Hogset A., Demeester J., De Smedt S.C. Biodegradable dextran nanogels for RNA interference: focusing on endosomal escape and intracellular siRNA delivery. Adv. Funct. Mater. 2009, 19:1406-1415.
26. Raemdonck K., Naeye B., Hogset A., Demeester J., De Smedt S.C. Prolonged gene silencing by combining siRNA nanogels and photochemical internalization. J. Control. Release 2010, 145:281-288.
27. Berg K., Folini M., Prasmickaite L., Selbo P.K., Bonsted A., Engesaeter B.O., Zaffaroni N., Weyergang A., Dietze A., Maelandsmo G.M., Wagner E., Norum O.J., Hogset A. Photochemical internalization: a new tool for drug delivery. Curr. Pharm. Biotechnol. 2007, 8:362-372.
28. Berg K., Selbo P.K., Prasmickaite L., Tjelle T.E., Sandvig K., Moan J., Gaudernack G., Fodstad O., Kjolsrud S., Anholt H., Rodal G.H., Rodal S.K., Hogset A. Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. Cancer Res. 1999, 59:1180-1183.
29. Selbo P.K., Weyergang A., Hogset A., Norum O.J., Berstad M.B., Vikdal M., Berg K. Photochemical internalization provides time- and space-controlled endolysosomal escape of therapeutic molecules. J. Control. Release 2010, 148:2-12.
30. Jensen L.B., Griger J., Naeye B., Varkouhi A.K., Raemdonck K., Schiffelers R., Lammers T., Storm G., De Smedt S.C., Sproat B.S., Nielsen H.M., Foged C. Comparison of polymeric siRNA nanocarriers in a murine LPS-activated macrophage cell line: gene silencing, toxicity and off-target gene expression. Pharm. Res. 2012, 29:669-682.
31. Naeye B., Raemdonck K., Remaut K., Sproat B., Demeester J., De Smedt S.C. PEGylation of biodegradable dextran nanogels for siRNA delivery. Eur. J. Pharm. Sci. 2010, 40:342-351.
32. Naeye B., Deschout H., Roding M., Rudemo M., Delanghe J., Devreese K., Demeester J., Braeckmans K., De Smedt S.C., Raemdonck K. Hemocompatibility of siRNA loaded dextran nanogels. Biomaterials 2011, 32:9120-9127.
33. Tripathi S.K., Goyal R., Gupta K.C. Surface modification of crosslinked dextran nanoparticles influences transfection efficiency of dextran-polyethylenimine nanocomposites. Soft Matter 2011, 7:11360-11371.
34. Susa M., Iyer A.K., Ryu K., Choy E., Hornicek F.J., Mankin H., Milane L., Amiji M.M., Duan Z. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One 2010, 5:e10764.
35. Bellamy W.T., Dalton W.S. Multidrug resistance in the laboratory and clinic. Adv. Clin. Chem. 1994, 31:1-61.
36. Bachelder E.M., Beaudette T.T., Broaders K.E., Frechet J.M., Albrecht M.T., Mateczun A.J., Ainslie K.M., Pesce J.T., Keane-Myers A.M. In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants. Mol. Pharm. 2010, 7:826-835.
37. Broaders K.E., Cohen J.A., Beaudette T.T., Bachelder E.M., Frechet J.M. Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:5497-5502.
38. Cohen J.A., Beaudette T.T., Cohen J.L., Broaders K.E., Bachelder E.M., Frechet J.M. Acetal-modified dextran microparticles with controlled degradation kinetics and surface functionality for gene delivery in phagocytic and non-phagocytic cells. Adv. Mater. 2010, 22:3593-3597.
39. Thomas T., Thomas T.J. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol. Life Sci. 2001, 58:244-258.
40. Cohen J.L., Schubert S., Wich P.R., Cui L., Cohen J.A., Mynar J.L., Frechet J.M. Acid-degradable cationic dextran particles for the delivery of siRNA therapeutics. Bioconjug. Chem. 2011, 22:1056-1065.
41. Delair T. Colloidal polyelectrolyte complexes of chitosan and dextran sulfate towards versatile nanocarriers of bioactive molecules. Eur. J. Pharm. Biopharm. 2011, 78:10-18.
42. Tiyaboonchai W., Woiszwillo J., Middaugh C.R. Formulation and characterization of DNA-polyethylenimine-dextran sulfate nanoparticles. Eur. J. Pharm. Sci. 2003, 19:191-202.
43. Tiyaboonchai W., Woiszwillo J., Sims R.C., Middaugh C.R. Insulin containing polyethylenimine-dextran sulfate nanoparticles. Int. J. Pharm. 2003, 255:139-151.
44. Cho H.J., Chong S., Chung S.J., Shim C.K., Kim D.D. Poly-l-arginine and dextran sulfate-based nanocomplex for epidermal growth factor receptor (EGFR) siRNA delivery: its application for head and neck cancer treatment. Pharm. Res. 2012, 29:1007-1019.
45. Kang H.C., Bae Y.H. Co-delivery of small interfering RNA and plasmid DNA using a polymeric vector incorporating endosomolytic oligomeric sulfonamide. Biomaterials 2011, 32:4914-4924.
46. Zorzi G.K., Parraga J.E., Seijo B., Sanchez A. Hybrid nanoparticle design based on cationized gelatin and the polyanions dextran sulfate and chondroitin sulfate for ocular gene therapy. Macromol. Biosci. 2011, 11:905-913.
47. Tseng W.C., Fang T.Y., Su L.Y., Tang C.H. Dependence of transgene expression and the relative buffering capacity of dextran-grafted polyethylenimine. Mol. Pharm. 2005, 2:224-232.
48. Tseng W.C., Tang C.H., Fang T.Y. The role of dextran conjugation in transfection mediated by dextran-grafted polyethylenimine. J. Gene Med. 2004, 6:895-905.
49. Tseng W.C., Jong C.M. Improved stability of polycationic vector by dextran-grafted branched polyethylenimine. Biomacromolecules 2003, 4:1277-1284.
50. Godbey W.T., Wu K.K., Mikos A.G. Size matters: molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle. J. Biomed. Mater. Res. 1999, 45:268-275.
51. Morimoto K., Nishikawa M., Kawakami S., Nakano T., Hattori Y., Fumoto S., Yamashita F., Hashida M. Molecular weight-dependent gene transfection activity of unmodified and galactosylated polyethyleneimine on hepatoma cells and mouse liver. Mol. Ther. 2003, 7:254-261.
52. Thomas M., Ge Q., Lu J.J., Chen J., Klibanov A.M. Cross-linked small polyethylenimines: while still nontoxic, deliver DNA efficiently to mammalian cells in vitro and in vivo. Pharm. Res. 2005, 22:373-380.
53. Philipp A., Zhao X.B., Tarcha P., Wagner E., Zintchenko A. Hydrophobically modified oligoethylenimines as highly efficient transfection agents for siRNA delivery. Bioconjug. Chem. 2009, 20:2055-2061.
54. Sun Y.X., Xiao W., Cheng S.X., Zhang X.Z., Zhuo R.X. Synthesis of (Dex-HMDI)-g-PEIs as effective and low cytotoxic nonviral gene vectors. J. Control. Release 2008, 128:171-178.
55. Sun Y.X., Zhang X.Z., Cheng H., Cheng S.X., Zhuo R.X. A low-toxic and efficient gene vector: carboxymethyl dextran-graft-polyethylenimine. J. Biomed. Mater. Res. Part A 2008, 84:1102-1110.
56. Jiang D., Salem A.K. Optimized dextran-polyethylenimine conjugates are efficient non-viral vectors with reduced cytotoxicity when used in serum containing environments. Int. J. Pharm. 2012, 427:71-79.
57. Sun K., Wang J., Zhang J., Hua M., Liu C.S., Chen T.Y. Dextran-g-PEI nanoparticles as a carrier for co-delivery of adriamycin and plasmid into osteosarcoma cells. Int. J. Biol. Macromol. 2011, 49:173-180.
58. Azzam T., Eliyahu H., Shapira L., Linial M., Barenholz Y., Domb A.J. Polysaccharide-oligoamine based conjugates for gene delivery. J. Med. Chem. 2002, 45:1817-1824.
59. Hosseinkhani H., Azzam T., Tabata Y., Domb A.J. Dextran-spermine polycation: an efficient nonviral vector for in vitro and in vivo gene transfection. Gene Ther. 2004, 11:194-203.
60. Azzam T., Eliyahu H., Makovitzki A., Linial M., Domb A.J. Hydrophobized dextran-spermine conjugate as potential vector for in vitro gene transfection. J. Control. Release 2004, 96:309-323.
61. Eliyahu H., Joseph A., Azzam T., Barenholz Y., Domb A.J. Dextran-spermine-based polyplexes-evaluation of transgene expression and of local and systemic toxicity in mice. Biomaterials 2006, 27:1636-1645.
62. Yang J., Liu Y., Wang H., Liu L., Wang W., Wang C., Wang Q., Liu W. The biocompatibility of fatty acid modified dextran-agmatine bioconjugate gene delivery vector. Biomaterials 2012, 33:604-613.
63. Molderings G.J., Haenisch B. Agmatine (decarboxylated l-arginine): physiological role and therapeutic potential. Pharmacol. Ther. 2012, 133:351-365.
64. Thomas J.J., Rekha M.R., Sharma C.P. Dextran-protamine polycation: an efficient nonviral and haemocompatible gene delivery system. Colloids Surf. B: Biointerfaces 2010, 81:195-205.
65. Sorgi F.L., Bhattacharya S., Huang L. Protamine sulfate enhances lipid-mediated gene transfer. Gene Ther. 1997, 4:961-968.
66. Delgado D., del Pozo-Rodriguez A., Solinis M.A., viles-Triqueros M., Weber B.H.F., Fernandez E., Gascon A.R. Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis. Hum. Gene Ther. 2012, 23:345-355.
67. Thomas J.J., Rekha M.R., Sharma C.P. Unraveling the intracellular efficacy of dextran-histidine polycation as an efficient nonviral gene delivery system. Mol. Pharm. 2012, 9:121-134.
68. Thomas J.J., Rekha M.R., Sharma C.P. Dextran-glycidyltrimethylammonium chloride conjugate/DNA nanoplex: a potential non-viral and haemocompatible gene delivery system. Int. J. Pharm. 2010, 389:195-206.
69. Onishi Y., Eshita Y., Murashita A., Mizuno M., Yoshida J. Characteristics of DEAE-dextran-MMA graft copolymer as a nonviral gene carrier. Nanomedicine 2007, 3:184-191.
70. Poon Z., Lee J.B., Morton S.W., Hammond P.T. Controlling in vivo stability and biodistribution in electrostatically assembled nanoparticles for systemic delivery. Nano Lett. 2011, 11:2096-2103.
71. Xiao K., Li Y.P., Luo J.T., Lee J.S., Xiao W.W., Gonik A.M., Agarwal R.G., Lam K.S. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 2011, 32:3435-3446.
72. Maruyama A., Ishihara T., Kim J.S., Kim S.W., Akaike T. Design of multi-layered nanoparticles as a DNA carrier. Colloids Surf., A Physicochem. Eng. Asp. 1999, 153:439-443.
73. Zimmer A. Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers. Methods-A Companion to Methods in Enzymology 1999, 18:286-295.
74. Zobel H.P., Kreuter J., Werner D., Noe C.R., Kumel G., Zimmer A. Cationic polyhexylcyanoacrylate nanoparticles as carriers for antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 1997, 7:483-493.
75. Delgado D., Gascon A.R., del Pozo-Rodriguez A., Echevarria E., de Garibay A.P.R., Rodriguez J.M., Solinis M.A. Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: in vitro characterization and in vivo transfection after intravenous administration to mice. Int. J. Pharm. 2012, 425:35-43.
76. Holzerny P., Ajdini B., Heusermann W., Bruno K., Schuleit M., Meinel L., Keller M. Biophysical properties of chitosan/siRNA polyplexes: profiling the polymer/siRNA interactions and bioactivity. J. Control. Release 2012, 157:297-304.
77. Janes K.A., Calvo P., Alonso M.J. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv. Drug Deliv. Rev. 2001, 47:83-97.
78. Mao S., Sun W., Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv. Drug Deliv. Rev. 2010, 62:12-27.
79. Rao S.B., Sharma C.P. Use of chitosan as a biomaterial: studies on its safety and hemostatic potential. J. Biomed. Mater. Res. 1997, 34:21-28.
80. Garcia-Fuentes M., Alonso M.J. Chitosan-based drug nanocarriers: where do we stand?. J. Control. Release 2012, 161:496-504.
81. Riva R., Ragelle H., des Rieux A., Duhem N., Jerome C., Preat V. Chitosan and chitosan derivatives in drug delivery and tissue engineering. Chitosan Biomater. II 2011, 244:19-44.
82. van d.L., Verhoef I.J.C., Borchard G., Junginger H.E. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur. J. Pharm. Sci. 2001, 14:201-207.
83. Plapied L., Vandermeulen G., Vroman B., Preat V., des Rieux A. Bioadhesive nanoparticles of fungal chitosan for oral DNA delivery. Int. J. Pharm. 2010, 398:210-218.
84. Dash M., Chiellini F., Ottenbrite R.M., Chiellini E. Chitosan-A versatile semi-synthetic polymer in biomedical applications. Prog. Polym. Sci. 2011, 36:981-1014.
85. Rudzinski W.E., Aminabhavi T.M. Chitosan as a carrier for targeted delivery of small interfering RNA. Int. J. Pharm. 2010, 399:1-11.
86. Thanou M., Florea B.I., Geldof M., Junginger H.E., Borchard G. Quaternized chitosan oligomers as novel gene delivery vectors in epithelial cell lines. Biomaterials 2002, 23:153-159.
87. Csaba N., Koping-Hoggard M., Alonso M.J. Ionically crosslinked chitosan/tripolyphosphate nanoparticles for oligonucleotide and plasmid DNA delivery. Int. J. Pharm. 2009, 382:205-214.
88. Lee D., Zhang W., Shirley S.A., Kong X., Hellermann G.R., Lockey R.F., Mohapatra S.S. Thiolated chitosan/DNA nanocomplexes exhibit enhanced and sustained gene delivery. Pharm. Res. 2007, 24:157-167.
89. Malhotra M., Kulamarva A., Sebak S., Paul A., Bhathena J., Mirzaei M., Prakash S. Ultrafine chitosan nanoparticles as an efficient nucleic acid delivery system targeting neuronal cells. Drug Dev. Ind. Pharm. 2009, 35:719-726.
90. Ravina M., Cubillo E., Olmeda D., Novoa-Carballal R., Fernandez-Megia E., Riguera R., Sanchez A., Cano A., Alonso M.J. Hyaluronic acid/chitosan-g-poly(ethylene glycol) nanoparticles for gene therapy: an application for pDNA and siRNA delivery. Pharm. Res. 2010, 27:2544-2555.
91. Katas H., Alpar H.O. Development and characterisation of chitosan nanoparticles for siRNA delivery. J. Control. Release 2006, 115:216-225.
92. Gaspar V.M., Correia I.J., Sousa A., Silva F., Paquete C.M., Queiroz J.A., Sousa F. Nanoparticle mediated delivery of pure P53 supercoiled plasmid DNA for gene therapy. J. Control. Release 2011, 156:212-222.
93. Remaut K., Sanders N.N., Fayazpour F., Demeester J., De Smedt S.C. Influence of plasmid DNA topology on the transfection properties of DOTAP/DOPE lipoplexes. J. Control. Release 2006, 115:335-343.
94. Howard K.A., Rahbek U.L., Liu X.D., Damgaard C.K., Glud S.Z., Andersen M.O., Hovgaard M.B., Schmitz A., Nyengaard J.R., Besenbacher F., Kjems J. RNA interference in vitro and in vivo using a chitosan/siRNA nanoparticle system. Mol. Ther. 2006, 14:476-484.
95. Ji A.M., Su D., Che O., Li W.S., Sun L., Zhang Z.Y., Yang B., Xu F. Functional gene silencing mediated by chitosan/siRNA nanocomplexes. Nanotechnology 2009, 20.
96. Jean M., Smaoui F., Lavertu M., Methot S., Bouhdoud L., Buschmann M.D., Merzouki A. Chitosan-plasmid nanoparticle formulations for IM and SC delivery of recombinant FGF-2 and PDGF-BB or generation of antibodies. Gene Ther. 2009, 16:1097-1110.
97. Klausner E.A., Zhang Z., Chapman R.L., Multack R.F., Volin M.V. Ultrapure chitosan oligomers as carriers for corneal gene transfer. Biomaterials 2010, 31:1814-1820.
98. Zhao X., Yu S.B., Wu F.L., Mao Z.B., Yu C.L. Transfection of primary chondrocytes using chitosan-pEGFP nanoparticles. J. Control. Release 2006, 112:223-228.
99. Moreira C., Oliveira H., Pires L.R., Simoes S., Barbosa M.A., Pego A.P. Improving chitosan-mediated gene transfer by the introduction of intracellular buffering moieties into the chitosan backbone. Acta Biomater. 2009, 5:2995-3006.
100. Lai W.F., Lin M.C.M. Nucleic acid delivery with chitosan and its derivatives. J. Control. Release 2009, 134:158-168.
101. Verheul R.J., van der Wal S., Hennink W.E. Tailorable thiolated trimethyl chitosans for covalently stabilized nanoparticles. Biomacromolecules 2010, 11:1965-1971.
102. Varkouhi A.K., Verheul R.J., Schiffelers R.M., Lammers T., Storm G., Hennink W.E. Gene silencing activity of siRNA polyplexes based on thiolated N,N,N-trimethylated chitosan. Bioconjug. Chem. 2010, 21:2339-2346.
103. Mok H., Lee S.H., Park J.W., Park T.G. Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nat. Mater. 2010, 9:272-278.
104. Lee S.J., Huh M.S., Lee S.Y., Min S., Lee S., Koo H., Chu J.U., Lee K.E., Jeon H., Choi Y., Choi K., Byun Y., Jeong S.Y., Park K., Kim K., Kwon I.C. Tumor-homing poly-siRNA/glycol chitosan self-cross-linked nanoparticles for systemic siRNA delivery in cancer treatment. Angew. Chem. Int. Ed Engl. 2012, 51:7203-7207.
105. Zhao R., Sun B., Liu T., Liu Y., Zhou S., Zuo A., Liang D. Optimize nuclear localization and intra-nucleus disassociation of the exogene for facilitating transfection efficacy of the chitosan. Int. J. Pharm. 2011, 413:254-259.
106. Parelkar S.S., Chan-Seng D., Emrick T. Reconfiguring polylysine architectures for controlling polyplex binding and non-viral transfection. Biomaterials 2011, 32:2432-2444.
107. Lentacker I., Vandenbroucke R.E., Lucas B., Demeester J., De Smedt S.C., Sanders N.N. New strategies for nucleic acid delivery to conquer cellular and nuclear membranes. J. Control. Release 2008, 132:279-288.
108. Jere D., Jiang H.L., Kim Y.K., Arote R., Choi Y.J., Yun C.H., Cho M.H., Cho C.S. Chitosan-graft-polyethylenimine for Akt1 siRNA delivery to lung cancer cells. Int. J. Pharm. 2009, 378:194-200.
109. Tripathi S.K., Goyal R., Kumar P., Gupta K.C. Linear polyethylenimine-graft-chitosan copolymers as efficient DNA/siRNA delivery vectors in vitro and in vivo. Nanomedicine 2012, 8:337-345.
110. Tripathi S.K., Goyal R., Kashyap M.P., Pant A.B., Haq W., Kumar P., Gupta K.C. Depolymerized chitosans functionalized with bPEI as carriers of nucleic acids and tuftsin-tethered conjugate for macrophage targeting. Biomaterials 2012, 33:4204-4219.
111. Huh M.S., Lee S.Y., Park S., Lee S., Chung H., Lee S., Choi Y., Oh Y.K., Park J.H., Jeong S.Y., Choi K., Kim K., Kwon I.C. Tumor-homing glycol chitosan/polyethylenimine nanoparticles for the systemic delivery of siRNA in tumor-bearing mice. J. Control. Release 2010, 144:134-143.
112. Duan Y.H., Guan X.P., Ge J., Quan D.P., Zhuo Y.H., Ye H.H., Shao T.T. Cationic nano-copolymers mediated IKK beta targeting siRNA inhibit the proliferation of human Tenon's capsule fibroblasts in vitro. Mol. Vis. 2008, 14:2616-2628.
113. Ditto A.J., Shah P.N., Gump L.R., Yun Y.H. Nanospheres formulated from l-tyrosine polyphosphate exhibiting sustained release of polyplexes and in vitro controlled transfection properties. Mol. Pharm. 2009, 6:986-995.
114. Ghosn B., Singh A., Li M., Vlassov A.V., Burnett C., Puri N., Roy K. Efficient gene silencing in lungs and liver using imidazole-modified chitosan as a nanocarrier for small interfering RNA. Oligonucleotides 2010, 20:163-172.
115. Pires L.R., Oliveira H., Barrias C.C., Sampaio P., Pereira A.J., Maiato H., Simoes S., Pego A.P. Imidazole-grafted chitosan-mediated gene delivery: in vitro study on transfection, intracellular trafficking and degradation. Nanomedicine (Lond.) 2011, 6:1499-1512.
116. Ghosn B., Kasturi S.P., Roy K. Enhancing polysaccharide-mediated delivery of nucleic acids through functionalization with secondary and tertiary amines. Curr. Top. Med. Chem. 2008, 8:331-340.
117. Chang K.L., Higuchi Y., Kawakami S., Yamashita F., Hashida M. Efficient gene transfection by histidine-modified chitosan through enhancement of endosomal escape. Bioconjug. Chem. 2010, 21:1087-1095.
118. Kim T.H., Ihm J.E., Choi Y.J., Nah J.W., Cho C.S. Efficient gene delivery by urocanic acid-modified chitosan. J. Control. Release 2003, 93:389-402.
119. Zhai X.Y., Sun P., Luo Y.F., Ma C.N., Xu J., Liu W.G. Guanidinylation: a simple way to fabricate cell penetrating peptide analogue-modified chitosan vector for enhanced gene delivery. J. Appl. Polym. Sci. 2011, 121:3569-3578.
120. Luo Y., Ling Y., Guo W.S., Pang J., Liu W.P., Fang Y.Q., Wen X.Q., Wei K., Gao X. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells. J. Control. Release 2010, 147:278-288.
121. Jones A.T. Gateways and tools for drug delivery: endocytic pathways and the cellular dynamics of cell penetrating peptides. Int. J. Pharm. 2008, 354:34-38.
122. Wender P.A., Galliher W.C., Goun E.A., Jones L.R., Pillow T.H. The design of guanidinium-rich transporters and their internalization mechanisms. Adv. Drug Deliv. Rev. 2008, 60:452-472.
123. Elfinger M., Geiger J., Hasenpusch G., Uzgun S., Sieverling N., Aneja M.K., Maucksch C., Rudolph C. Targeting of the beta(2)-adrenoceptor increases nonviral gene delivery to pulmonary epithelial cells in vitro and lungs in vivo. J. Control. Release 2009, 135:234-241.
124. Jiang H.L., Kim Y.K., Arote R., Jere D., Quan J.S., Yu J.H., Choi Y.J., Nah J.W., Cho M.H., Cho C.S. Mannosylated chitosan-graft-polyethylenimine as a gene carrier for Raw 264.7 cell targeting. Int. J. Pharm. 2009, 375:133-139.
125. Cheng M., Li Q., Wan T., Hong X., Chen H., He B., Cheng Z., Xu H., Ye T., Zha B., Wu J., Zhou R. Synthesis and efficient hepatocyte targeting of galactosylated chitosan as a gene carrier in vitro and in vivo. J. Biomed. Mater. Res. B Appl. Biomater. 2011, 99:70-80.
126. Jiang H.L., Kwon J.T., Kim E.M., Kim Y.K., Arote R., Jere D., Jeong H.J., Jang M.K., Nah J.W., Xu C.X., Park I.K., Cho M.H., Cho C.S. Galactosylated poly(ethylene glycol)-chitosan-graft-polyethylenimine as a gene carrier for hepatocyte-targeting. J. Control. Release 2008, 131:150-157.
127. Jiang H.L., Xu C.X., Kim Y.K., Arote R., Jere D., Lim H.T., Cho M.H., Cho C.S. The suppression of lung tumorigenesis by aerosol-delivered folate-chitosan-graft-polyethylenimine/Akt1 shRNA complexes through the Akt signaling pathway. Biomaterials 2009, 30:5844-5852.
128. Lee J., Yun K.S., Choi C.S., Shin S.H., Ban H.S., Rhim T., Lee S.K., Lee K.Y. T cell-specific siRNA delivery using antibody-conjugated chitosan nanoparticles. Bioconjug. Chem. 2012, 23:1174-1180.
129. Han H.D., Mangala L.S., Lee J.W., Shahzad M.M., Kim H.S., Shen D., Nam E.J., Mora E.M., Stone R.L., Lu C., Lee S.J., Roh J.W., Nick A.M., Lopez-Berestein G., Sood A.K. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin. Cancer Res. 2010, 16:3910-3922.
130. Schiffelers R.M., Ansari A., Xu J., Zhou Q., Tang Q.Q., Storm G., Molema G., Lu P.Y., Scaria P.V., Woodle M.C. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004, 32.
131. Oliveira H., Pires L.R., Fernandez R., Martins M.C., Simoes S., Pego A.P. Chitosan-based gene delivery vectors targeted to the peripheral nervous system. J. Biomed. Mater. Res. Part A 2010, 95:801-810.
132. Oliveira H., Fernandez R., Pires L.R., Martins M.C., Simoes S., Barbosa M.A., Pego A.P. Targeted gene delivery into peripheral sensorial neurons mediated by self-assembled vectors composed of poly(ethylene imine) and tetanus toxin fragment c. J. Control. Release 2010, 143:350-358.
133. Duceppe N., Tabrizian M. Advances in using chitosan-based nanoparticles for in vitro and in vivo drug and gene delivery. Expert Opin. Drug Deliv. 2010, 7:1191-1207.
134. Liao Z.X., Ho Y.C., Chen H.L., Peng S.F., Hsiao C.W., Sung H.W. Enhancement of efficiencies of the cellular uptake and gene silencing of chitosan/siRNA complexes via the inclusion of a negatively charged poly(gamma-glutamic acid). Biomaterials 2010, 31:8780-8788.
135. Peng S.F., Yang M.J., Su C.J., Chen H.L., Lee P.W., Wei M.C., Sung H.W. Effects of incorporation of poly(gamma-glutamic acid) in chitosan/DNA complex nanoparticles on cellular uptake and transfection efficiency. Biomaterials 2009, 30:1797-1808.
136. Lu H.D., Zhao H.Q., Wang K., Lv L.L. Novel hyaluronic acid-chitosan nanoparticles as non-viral gene delivery vectors targeting osteoarthritis. Int. J. Pharm. 2011, 420:358-365.
137. Lee D.W., Yun K.S., Ban H.S., Choe W., Lee S.K., Lee K.Y. Preparation and characterization of chitosan/polyguluronate nanoparticles for siRNA delivery. J. Control. Release 2009, 139:146-152.
138. Chung Y.I., Kim J.C., Kim Y.H., Tae G., Lee S.Y., Kim K., Kwon I.C. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting. J. Control. Release 2010, 143:374-382.
139. Nafee N., Taetz S., Schneider M., Schaefer U.F., Lehr C.M. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine: NBM 2007, 3:173-183.
140. Taetz S., Nafee N., Beisner J., Piotrowska K., Baldes C., Murdter T.E., Huwer H., Schneider M., Schaefer U.F., Klotz U., Lehr C.M. The influence of chitosan content in cationic chitosan/PLGA nanoparticles on the delivery efficiency of antisense 2'-O-methyl-RNA directed against telomerase in lung cancer cells. Eur. J. Pharm. Biopharm. 2009, 72:358-369.
141. Yuan X.D., Shah B.A., Kotadia N.K., Li J.A., Gu H., Wu Z.Q. The development and mechanism studies of cationic chitosan-modified biodegradable PLGA nanoparticles for efficient siRNA drug delivery. Pharm. Res. 2010, 27:1285-1295.
142. Tahara K., Yamamoto H., Hirashima N., Kawashima Y. Chitosan-modified poly(d,l-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects. Eur. J. Pharm. Biopharm. 2010, 74:421-426.
143. Pille J.Y., Li H., Blot E., Bertrand J.R., Pritchard L.L., Opolon P., Maksimenko A., Lu H., Vannier J.P., Soria J., Malvy C., Soria C. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum. Gene Ther. 2006, 17:1019-1026.
144. de Martimprey H., Bertrand J.R., Fusco A., Santoro M., Couvreur P., Vauthier C., Malvy C. siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Res. 2008, 36.
145. de Martimprey H., Bertrand J.R., Malvy C., Couvreur P., Vauthier C. New core-shell nanoparticles for the intravenous delivery of siRNA to experimental thyroid papillary carcinoma. Pharm. Res. 2010, 27:498-509.
146. Maksimenko A., Polard V., Villemeur M., Elhamess H., Couvreur P., Bertrand J.R., Aboubakar M., Gottikh M., Malvy C. In vivo potentialities of EWS-Fli-1 targeted antisense oligonucleotides-nanospheres complexes, therapeutic oligonucleotides: transcriptional and translational strategies for silencing gene expression 2005, 1058:52-61.
147. Bertholon I., Vauthier C., Labarre D. Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide. Pharm. Res. 2006, 23:1313-1323.
148. Colonna C., Conti B., Genta I., Alpar O.H. Non-viral dried powders for respiratory gene delivery prepared by cationic and chitosan loaded liposomes. Int. J. Pharm. 2008, 364:108-118.
149. Wang W.X., Gao J.Q., Liang W.Q. Chitosan-coated liposomes for intracellular oligonucleotides delivery: characteristics and cell uptake behavior. Drug Deliv. 2011, 18:208-214.
150. Khatri K., Goya A.K., Gupta P.N., Mishra N., Mehta A., Vyas S.P. Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine 2008, 26:2225-2233.
151. Lapcik L., Lapcik L., De Smedt S., Demeester J., Chabrecek P. Hyaluronan: preparation, structure, properties, and applications. Chem. Rev. 1998, 98:2663-2684.
152. Yadav A.K., Mishra P., Agrawal G.P. An insight on hyaluronic acid in drug targeting and drug delivery. J. Drug Target. 2008, 16:91-107.
153. Kothapalli D., Zhao L., Hawthorne E.A., Cheng Y., Lee E., Pure E., Assoian R.K. Hyaluronan and CD44 antagonize mitogen-dependent cyclin D1 expression in mesenchymal cells. J. Cell Biol. 2007, 176:535-544.
154. Termeer C., Sleeman J.P., Simon J.C. Hyaluronan-magic glue for the regulation of the immune response?. Trends Immunol. 2003, 24:112-114.
155. Almond A. Hyaluronan. Cell Mol. Life Sci. 2007, 64:1591-1596.
156. Zeng C., Toole B.P., Kinney S.D., Kuo J.W., Stamenkovic I. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int. J. Cancer 1998, 77:396-401.
157. Jiang D.H., Liang J.R., Noble P.W. Hyaluronan as an immune regulator in human diseases. Physiol. Rev. 2011, 91:221-264.
158. Oh E.J., Park K., Kim K.S., Kim J., Yang J.A., Kong J.H., Lee M.Y., Hoffman A.S., Hahn S.K. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J. Control. Release 2010, 141:2-12.
159. Barbault-Foucher S., Gref R., Russo P., Guechot J., Bochot A. Design of poly-epsilon-caprolactone nanospheres coated with bioadhesive hyaluronic acid for ocular delivery. J. Control. Release 2002, 83:365-375.
160. Yerushalmi N., Arad A., Margalit R. Molecular and cellular studies of hyaluronic acid-modified liposomes as bioadhesive carriers for topical drug delivery in wound healing. Arch. Biochem. Biophys. 1994, 313:267-273.
161. Peer D., Margalit R. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int. J. Cancer 2004, 108:780-789.
162. Peer D., Florentin A., Margalit R. Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes. Biochim. Biophys. Acta 2003, 1612:76-82.
163. Eliaz R.E., Szoka F.C. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res. 2001, 61:2592-2601.
164. Kim K.S., Hur W., Park S.J., Hong S.W., Choi J.E., Goh E.J., Yoon S.K., Hahn S.K. Bioimaging for targeted delivery of hyaluronic acid derivatives to the livers in cirrhotic mice using quantum dots. ACS Nano 2010, 4:3005-3014.
165. Peer D., Margalit R. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 2004, 6:343-353.
166. Surace C., Arpicco S., Dufay-Wojcicki A., Marsaud V., Bouclier C., Clay D., Cattel L., Renoir J.M., Fattal E. Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells. Mol. Pharm. 2009, 6:1062-1073.
167. Kim A., Checkla D.M., Dehazya P., Chen W. Characterization of DNA-hyaluronan matrix for sustained gene transfer. J. Control. Release 2003, 2003(05/28):81-95.
168. Yun Y.H., Goetz D.J., Yellen P., Chen W. Hyaluronan microspheres for sustained gene delivery and site-specific targeting. Biomaterials 2004, 25:147-157.
169. Kim A.P., Yellen P., Yun Y.H., Azeloglu E., Chen W. Delivery of a vector encoding mouse hyaluronan synthase 2 via a crosslinked hyaluronan film. Biomaterials 2005, 26:1585-1593.
170. Lee H., Mok H., Lee S., Oh Y.K., Park T.G. Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. J. Control. Release 2007, 119:245-252.
171. Kim E.J., Shim G., Kim K., Kwon I.C., Oh Y.K., Shim C.K. Hyaluronic acid complexed to biodegradable poly l-arginine for targeted delivery of siRNAs. J. Gene Med. 2009, 11:791-803.
172. de la Fuente M., Seijo B., Alonso M.J. Bioadhesive hyaluronan-chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue. Gene Ther. 2008, 15:668-676.
173. Tammi R., Rilla K., Pienimaki J.P., MacCallum D.K., Hogg M., Luukkonen M., Hascall V.C., Tammi M. Hyaluronan enters keratinocytes by a novel endocytic route for catabolism. J. Biol. Chem. 2001, 276:35111-35122.
174. Evanko S.P., Wight T.N. Intracellular localization of hyaluronan in proliferating cells. J. Histochem. Cytochem. 1999, 47:1331-1342.
175. Contreras-Ruiz L., de la Fuente M., Parraga J.E., Lopez-Garcia A., Fernandez I., Seijo B., Sanchez A., Calonge M., Diebold Y. Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells. Mol. Vis. 2011, 17:279-290.
176. Bathori G., Cervenak L., Karadi I. Caveolae - an alternative endocytotic pathway for targeted drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 2004, 21:67-95.
177. Takei Y., Maruyama A., Ferdous A., Nishimura Y., Kawano S., Ikejima K., Okumura S., Asayama S., Nogawa M., Hashimoto M., Makino Y., Kinoshita M., Watanabe S., Akaike T., Lemasters J.J., Sato N. Targeted gene delivery to sinusoidal endothelial cells: DNA nanoassociate bearing hyaluronan-glycocalyx. FASEB J. 2004, 18:699-701.
178. Jiang G., Park K., Kim J., Kim K.S., Oh E.J., Kang H., Han S.E., Oh Y.K., Park T.G., Kwang Hahn S. Hyaluronic acid-polyethyleneimine conjugate for target specific intracellular delivery of siRNA. Biopolymers 2008, 89:635-642.
179. Kim J., Kim K.S., Jiang G., Kang H., Kim S., Kim B.S., Park M.H., Hahn S.K. In vivo real-time bioimaging of hyaluronic acid derivatives using quantum dots. Biopolymers 2008, 89:1144-1153.
180. Jiang G., Park K., Kim J., Kim K.S., Hahn S.K. Target specific intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis. Mol. Pharm. 2009, 6:727-737.
181. Park K., Hong S.W., Hur W., Lee M.Y., Yang J.A., Kim S.W., Yoon S.K., Hahn S.K. Target specific systemic delivery of TGF-beta siRNA/(PEI-SS)-g-HA complex for the treatment of liver cirrhosis. Biomaterials 2011, 32:4951-4958.
182. Park K., Lee M.Y., Kim K.S., Hahn S.K. Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine - hyaluronic acid conjugate. Biomaterials 2010, 31:5258-5265.
183. Choi K.Y., Chung H., Min K.H., Yoon H.Y., Kim K., Park J.H., Kwon I.C., Jeong S.Y. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials 2010, 31:106-114.
184. Koo H., Moon H., Han H., Na J.H., Huh M.S., Park J.H., Woo S.J., Park K.H., Chan Kwon I., Kim K., Kim H. The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection. Biomaterials 2012, 33:3485-3493.
185. Yoo H.S., Lee J.E., Chung H., Kwon I.C., Jeong S.Y. Self-assembled nanoparticles containing hydrophobically modified glycol chitosan for gene delivery. J. Control. Release 2005, 103:235-243.
186. Shen Y., Wang B., Lu Y., Ouahab A., Li Q., Tu J. A novel tumor-targeted delivery system with hydrophobized hyaluronic acid-spermine conjugates (HHSCs) for efficient receptor-mediated siRNA delivery. Int. J. Pharm. 2011, 414:233-243.
187. Zaki N.M., Nasti A., Tirelli N. Nanocarriers for cytoplasmic delivery: cellular uptake and intracellular fate of chitosan and hyaluronic acid-coated chitosan nanoparticles in a phagocytic cell model. Macromol. Biosci. 2011, 11:1747-1760.
188. Rejman J., Oberle V., Zuhorn I.S., Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem. J. 2004, 377:159-169.
189. Vercauteren D., Vandenbroucke R.E., Jones A.T., Rejman J., Demeester J., De Smedt S.C., Sanders N.N., Braeckmans K. The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls. Mol. Ther. 2010, 18:561-569.
190. Ruponen M., Ronkko S., Honkakoski P., Pelkonen J., Tammi M., Urtti A. Extracellular glycosaminoglycans modify cellular trafficking of lipoplexes and polyplexes. J. Biol. Chem. 2001, 276:33875-33880.
191. Hornof M., de la Fuente M., Hallikainen M., Tammi R.H., Urtti A. Low molecular weight hyaluronan shielding of DNA/PEI polyplexes facilitates CD44 receptor mediated uptake in human corneal epithelial cells. J. Gene Med. 2008, 10:70-80.
192. Wang Y., Xu Z., Zhang R., Li W., Yang L., Hu Q. A facile approach to construct hyaluronic acid shielding polyplexes with improved stability and reduced cytotoxicity. Colloids Surf. B: Biointerfaces 2011, 84:259-266.
193. Ito T., Iida-Tanaka N., Niidome T., Kawano T., Kubo K., Yoshikawa K., Sato T., Yang Z., Koyama Y. Hyaluronic acid and its derivative as a multi-functional gene expression enhancer: protection from non-specific interactions, adhesion to targeted cells, and transcriptional activation. J. Control. Release 2006, 112:382-388.
194. Xu P.S., Quick G.K., Yeo Y. Gene delivery through the use of a hyaluronate-associated intracellularly degradable crosslinked polyethyleneimine. Biomaterials 2009, 30:5834-5843.
195. Peer D., Park E.J., Morishita Y., Carman C.V., Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008, 319:627-630.
196. Taetz S., Bochot A., Surace C., Arpicco S., Renoir J.M., Schaefer U.F., Marsaud V., Kerdine-Roemer S., Lehr C.M., Fattal E. Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells. Oligonucleotides 2009, 19:103-116.
197. Stern R., Asari A.A., Sugahara K.N. Hyaluronan fragments: an information-rich system. Eur. J. Cell Biol. 2006, 85:699-715.
198. Mizrahy S., Raz S.R., Hasgaard M., Liu H., Soffer-Tsur N., Cohen K., Dvash R., Landsman-Milo D., Bremer M.G., Moghimi S.M., Peer D. Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. J. Control. Release 2011, 156:231-238.
199. Ortiz M.C., Garcia Fernandez J.M., Benito J.M. Cyclodextrin-based gene delivery systems. Chem. Soc. Rev. 2011, 40:1586-1608.
200. Davis M.E., Brewster M.E. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discov. 2004, 3:1023-1035.
201. Irie T., Uekama K. Cyclodextrins in peptide and protein delivery. Adv. Drug Deliv. Rev. 1999, 36:101-123.
202. Redenti E., Pietra C., Gerloczy A., Szente L. Cyclodextrins in oligonucleotide delivery. Adv. Drug Deliv. Rev. 2001, 53:235-244.
203. Chaturvedi K., Ganguly K., Kulkarni A.R., Kulkarni V.H., Nadagouda M.N., Rudzinski W.E., Aminabhavi T.M. Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review. Expert Opin. Drug Deliv. 2011, 8:1455-1468.
204. Gonzalez H., Hwang S.J., Davis M.E. New class of polymers for the delivery of macromolecular therapeutics. Bioconjug. Chem. 1999, 10:1068-1074.
205. Hwang S.J., Bellocq N.C., Davis M.E. Effects of structure of beta-cyclodextrin-containing polymers on gene delivery. Bioconjug. Chem. 2001, 12:280-290.
206. Popielarski S.R., Mishra S., Davis M.E. Structural effects of carbohydrate-containing polycations on gene delivery. 3. Cyclodextrin type and functionalization. Bioconjug. Chem. 2003, 14:672-678.
207. Reineke T.M., Davis M.E. Structural effects of carbohydrate-containing polycations on gene delivery. 2. Charge center type. Bioconjug. Chem. 2003, 14:255-261.
208. Reineke T.M., Davis M.E. Structural effects of carbohydrate-containing polycations on gene delivery. 1. Carbohydrate size and its distance from charge centers. Bioconjug. Chem. 2003, 14:247-254.
209. Davis M.E., Pun S.H., Bellocq N.C., Reineke T.M., Popielarski S.R., Mishra S., Heidel J.D. Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers. Curr. Med. Chem. 2004, 11:179-197.
210. Mishra S., Heidel J.D., Webster P., Davis M.E. Imidazole groups on a linear, cyclodextrin-containing polycation produce enhanced gene delivery via multiple processes. J. Control. Release 2006, 116:179-191.
211. Sonawane N.D., Szoka F.C., Verkman A.S. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J. Biol. Chem. 2003, 278:44826-44831.
212. Pun S.H., Davis M.E. Development of a nonviral gene delivery vehicle for systemic application. Bioconjug. Chem. 2002, 13:630-639.
213. Bellocq N.C., Pun S.H., Jensen G.S., Davis M.E. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconj. Chem. 2003, 14:1122-1132.
214. Bartlett D.W., Davis M.E. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug. Chem. 2007, 18:456-468.
215. Bartlett D.W., Su H., Hildebrandt I.J., Weber W.A., Davis M.E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15549-15554.
216. Hu-Lieskovan S., Heidel J.D., Bartlett D.W., Davis M.E., Triche T.J. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 2005, 65:8984-8992.
217. Bartlett D.W., Davis M.E. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol. Bioeng. 2008, 99:975-985.
218. Heidel J.D., Liu J.Y., Yen Y., Zhou B., Heale B.S., Rossi J.J., Bartlett D.W., Davis M.E. Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin. Cancer Res. 2007, 13:2207-2215.
219. Rahman M.A., Amin A.R., Wang X., Zuckerman J.E., Choi C.H., Zhou B., Wang D., Nannapaneni S., Koenig L., Chen Z., Chen Z.G., Yen Y., Davis M.E., Shin D.M. Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth. J. Control. Release 2012, 159:384-392.
220. Zuckerman J.E., Choi C.H., Han H., Davis M.E. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:3137-3142.
221. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., Yen Y., Heidel J.D., Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
222. Brahmamdam P., Watanabe E., Unsinger J., Chang K.C., Schierding W., Hoekzema A.S., Zhou T.T., McDonough J.S., Holemon H., Heidel J.D., Coopersmith C.M., McDunn J.E., Hotchkiss R.S. Targeted delivery of siRNA to cell death proteins in sepsis. Shock 2009, 32:131-139.
223. Heidel J.D., Yu Z., Liu J.Y., Rele S.M., Liang Y., Zeidan R.K., Kornbrust D.J., Davis M.E. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:5715-5721.
224. Boe S.L., Longva A.S., Hovig E. Cyclodextrin-containing polymer delivery system for light-directed siRNA gene silencing. Oligonucleotides 2010, 20:175-182.
225. Norum O.J., Selbo P.K., Weyergang A., Giercksky K.E., Berg K. Photochemical internalization (PCI) in cancer therapy: from bench towards bedside medicine. J. Photochem. Photobiol. B 2009, 96:83-92.
226. Srinivasachari S., Reineke T.M. Versatile supramolecular pDNA vehicles via "click polymerization" of beta-cyclodextrin with oligoethyleneamines. Biomaterials 2009, 30:928-938.
227. Huang H., Tang G., Wang Q., Li D., Shen F., Zhou J., Yu H. Two novel non-viral gene delivery vectors: low molecular weight polyethylenimine cross-linked by (2-hydroxypropyl)-beta-cyclodextrin or (2-hydroxypropyl)-gamma-cyclodextrin. Chem. Commun. (Camb.) 2006, 2382-2384.
228. Huang H., Yu H., Li D., Liu Y., Shen F., Zhou J., Wang Q., Tang G. A novel co-polymer based on hydroxypropyl alpha-cyclodextrin conjugated to low molecular weight polyethylenimine as an in vitro gene delivery vector. Int. J. Mol. Sci. 2008, 9:2278-2289.
229. Huang H.L., Yu H., Tang G.P., Wang Q.Q., Li J. Low molecular weight polyethylenimine cross-linked by 2-hydroxypropyl-gamma-cyclodextrin coupled to peptide targeting HER2 as a gene delivery vector. Biomaterials 2010, 31:1830-1838.
230. Yao H., Ng S.S., Tucker W.O., Tsang Y.K.T., Man K., Wang X.M., Chow B.K.C., Kung H.F., Tang G.P., Lin M.C. The gene transfection efficiency of a folate-PEI600-cyclodextrin nanopolymer. Biomaterials 2009, 30:5793-5803.
231. Pun S.H., Bellocq N.C., Liu A., Jensen G., Machemer T., Quijano E., Schluep T., Wen S., Engler H., Heidel J., Davis M.E. Cyclodextrin-modified polyethylenimine polymers for gene delivery. Bioconjug. Chem. 2004, 15:831-840.
232. Zhang J.X., Sun H.L., Ma P.X. Host-guest interaction mediated polymeric assemblies: multifunctional nanoparticles for drug and gene delivery. Acs Nano 2010, 4:1049-1059.
233. Choi H.S., Yamashita A., Ooya T., Yui N., Akita H., Kogure K., Ito R., Harashima H. Sunflower-shaped cyclodextrin-conjugated poly(epsilon-lysine) polyplex as a controlled intracellular trafficking device. ChemBioChem 2005, 6:1986-1990.
234. Teijeiro-Osorio D., Remunan-Lopez C., Alonso M.J. Chitosan/cyclodextrin nanoparticles can efficiently transfect the airway epithelium in vitro. Eur. J. Pharm. Biopharm. 2009, 71:257-263.
235. Kulkarni A., Deng W., Hyun S.H., Thompson D.H. Development of a low toxicity, effective pDNA vector based on noncovalent assembly of bioresponsive amino-beta-cyclodextrin:adamantane-poly(vinyl alcohol)-poly(ethylene glycol) transfection complexes. Bioconj. Chem. 2012, 23:933-940.
236. Kulkarni A., Defrees K., Hyun S.H., Thompson D.H. Pendant polymer:amino-beta-cyclodextrin:siRNA guest:host nanoparticles as efficient vectors for gene silencing. J. Am. Chem. Soc. 2012, 134:7596-7599.
237. Petrovsky N., Cooper P.D. Carbohydrate-based immune adjuvants. Expert Rev. Vaccin. 2011, 10:523-537.
238. Song Y.B., Sun Y.X., Zhang X.Z., Zhou J.P., Zhang L.N. Homogeneous quaternization of cellulose in NaOH/urea aqueous solutions as gene carriers. Biomacromolecules 2008, 9:2259-2264.
239. Song Y.B., Wang H.Y., Zeng X.A., Sun Y.X., Zhang X.Z., Zhou J.P., Zhang L.N. Effect of molecular weight and degree of substitution of quaternized cellulose on the efficiency of gene transfection. Bioconjug. Chem. 2010, 21:1271-1279.
240. Mizu M., Koumoto K., Anada T., Matsumoto T., Numata M., Shinkai S., Nagasaki T., Sakurai K. A polysaccharide carrier for immunostimulatory CpG DNAs to enhance cytokine secretion. J. Am. Chem. Soc. 2004, 126:8372-8373.
241. Nagasaki T., Hojo M., Uno A., Satoh T., Koumoto K., Mizu M., Sakurai K., Shinkai S. Long-term expression with a cationic polymer derived from a natural polysaccharide: schizophyllan. Bioconjug. Chem. 2004, 15:249-259.
242. Mochizuki S., Sakurai K. A novel polysaccharide/polynucleotide complex and its application to bio-functional DNA delivery system. Polym. J. 2009, 41:343-353.
243. Takedatsu H., Mitsuyama K., Mochizuki S., Kobayashi T., Sakurai K., Takeda H., Fujiyama Y., Koyama Y., Nishihira J., Sata M. A new therapeutic approach using a schizophyllan-based drug delivery system for inflammatory bowel disease. Mol. Ther. 2012, 20:1234-1241.
244. Summerton J.E. A novel reagent for safe, effective delivery of substances into cells. Therapeutic Oligonucleotides: Transcriptional and Translational Strategies for Silencing Gene Expression, Annals of the New York Academy of Sciences 2005, vol. 1058:62-75. 10.1196/annals.1359.012.
245. Tesz G.J., Aouadi M., Prot M., Nicoloro S.M., Boutet E., Amano S.U., Goller A., Wang M., Guo C.A., Salomon W.E., Virbasius J.V., Baum R.A., O'Connor M.J., Soto E., Ostroff G.R., Czech M.P. Glucan particles for selective delivery of siRNA to phagocytic cells in mice. Biochem. J. 2011, 436:351-362.
246. Kankkunen P., Teirila L., Rintahaka J., Alenius H., Wolff H., Matikainen S. (1,3)-Beta-glucans activate both dectin-1 and NLRP3 inflammasome in human macrophages. J. Immunol. 2010, 184:6335-6342.
247. Goodridge H.S., Wolf A.J., Underhill D.M. Beta-glucan recognition by the innate immune system. Immunol. Rev. 2009, 230:38-50.
248. Huang H., Ostroff G.R., Lee C.K., Specht C.A., Levitz S.M. Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded beta-glucan particles. MBio 2010, 1. e00164-10.
249. Aouadi M., Tesz G.J., Nicoloro S.M., Wang M., Chouinard M., Soto E., Ostroff G.R., Czech M.P. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009, 458:1180-1184.
250. Lee K.Y., Mooney D.J. Alginate: properties and biomedical applications. Prog. Polym. Sci. 2012, 37:106-126.
251. Hunter A.C. Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv. Drug Deliv. Rev. 2006, 58:1523-1531.
252. Patnaik S., Aggarwal A., Nimesh S., Goel A., Ganguli M., Saini N., Singh Y., Gupta K.C. PEI-alginate nanocomposites as efficient in vitro gene transfection agents. J. Control. Release 2006, 114:398-409.
253. Patnaik S., Arif M., Pathak A., Singh N., Gupta K.C. PEI-alginate nanocomposites: efficient non-viral vectors for nucleic acids. Int. J. Pharm. 2010, 385:194-202.
254. Jiang G., Min S.H., Oh E.J., Hahn S.K. DNA/PEI/alginate polyplex as an efficient in vivo gene delivery system. Biotechnol. Bioprocess Eng. 2007, 12:684-689.
255. He W., Guo Z.H., Wen Y.T., Wang Q., Xie B.M., Zhu S.F., Wang Q.M. Alginate-graft-PEI as a gene delivery vector with high efficiency and low cytotoxicity. J. Biomater. Sci. Polym. Ed. 2012, 23:315-331.
256. Eliyahu H., Siani S., Azzam T., Domb A.J., Barenholz Y. Relationships between chemical composition, physical properties and transfection efficiency of polysaccharide-spermine conjugates. Biomaterials 2006, 27:1646-1655.
257. Cheng K.C., Demirci A., Catchmark J.M. Pullulan: biosynthesis, production, and applications. Appl. Microbiol. Biotechnol. 2011, 92:29-44.
258. Jo J., Yamamoto M., Matsumoto K., Nakamura T., Tabata Y. Liver targeting of plasmid DNA with a cationized pullulan for tumor suppression. J. Nanosci. Nanotechnol. 2006, 6:2853-2859.
259. Kanatani I., Ikai T., Okazaki A., Jo J., Yamamoto M., Imamura M., Kanematsu A., Yamamoto S., Ito N., Ogawa O., Tabata Y. Efficient gene transfer by pullulan-spermine occurs through both clathrin- and raft/caveolae-dependent mechanisms. J. Control. Release 2006, 116:75-82.
260. Rekha M.R., Sharma C.P. Blood compatibility and in vitro transfection studies on cationically modified pullulan for liver cell targeted gene delivery. Biomaterials 2009, 30:6655-6664.
261. Kaneo Y., Tanaka T., Nakano T., Yamaguchi Y. Evidence for receptor-mediated hepatic uptake of pullulan in rats. J. Control. Release 2001, 70:365-373.
262. Maxwell E.G., Belshaw N.J., Waldron K.W., Morris V.J. Pectin - an emerging new bioactive food polysaccharide. Trends Food Sci. Technol. 2012, 24:64-73.
263. Katav T., Liu L., Traitel T., Goldbart R., Wolfson M., Kost J. Modified pectin-based carrier for gene delivery: cellular barriers in gene delivery course. J. Control. Release 2008, 130:183-191.
264. Opanasopit P., Apirakaramwong A., Ngawhirunpat T., Rojanarata T., Ruktanonchai U. Development and characterization of pectinate micro/nanoparticles for gene delivery. AAPS PharmSciTech 2008, 9:67-74.
265. Zhou Y.F., Yang B., Ren X.Y., Liu Z.Z., Deng Z., Chen L.M., Deng Y.B., Zhang L.M., Yang L.Q. Hyperbranched cationic amylopectin derivatives for gene delivery. Biomaterials 2012, 33:4731-4740.